Lifecore Biomedical (NASDAQ:LFCR) Upgraded at Barrington Research

Lifecore Biomedical (NASDAQ:LFCR) was upgraded by equities researchers at Barrington Research from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday. The brokerage presently has a $5.50 target price on the stock. Barrington Research’s price target would suggest a potential upside of 26.15% from the company’s previous close.

A number of other analysts also recently issued reports on LFCR. Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a report on Thursday, January 22nd. Zacks Research upgraded shares of Lifecore Biomedical to a “hold” rating in a report on Thursday, January 1st. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Lifecore Biomedical currently has a consensus rating of “Hold” and an average price target of $5.50.

Lifecore Biomedical Trading Down 33.3%

NASDAQ LFCR opened at $4.36 on Tuesday. Lifecore Biomedical has a 52 week low of $4.20 and a 52 week high of $8.98. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.67 and a current ratio of 2.80. The stock’s 50 day moving average price is $7.54 and its two-hundred day moving average price is $7.49. The stock has a market capitalization of $163.37 million, a price-to-earnings ratio of -4.07 and a beta of 0.62.

Institutional Investors Weigh In On Lifecore Biomedical

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Lifecore Biomedical by 14.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock valued at $104,000 after buying an additional 1,886 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its stake in Lifecore Biomedical by 8.4% in the second quarter. Steward Partners Investment Advisory LLC now owns 32,761 shares of the company’s stock valued at $266,000 after acquiring an additional 2,528 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock valued at $43,000 after acquiring an additional 2,786 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Lifecore Biomedical by 20.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock worth $137,000 after purchasing an additional 2,826 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Lifecore Biomedical by 28.4% in the 4th quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock valued at $132,000 after purchasing an additional 3,574 shares during the period. Institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.